Clinical trial
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients…
NCT00024440 · Genta Incorporated, Industry · Completed
Key facts
| NCT number | NCT00024440 |
|---|---|
| Title | Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Official title | Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia |
| Lead sponsor | Genta Incorporated, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, oblimersen sodium, cyclophosphamide, fludarabine phosphate |
| Start date | Jul 1, 2001 |
| Completion | Feb 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: